Japan’s Eisai was approved for a China launch of its antiepileptic (AED) drug Fycompa® as an adjunct treatment of partial onset seizures in epilepsy patients at least 12 years old. A first-in-class oral AED, Eisai describes Fycompa as a highly selective, noncompetitive AMPA receptor antagonist that reduces neuronal hyperexcitation by targeting glutamate activity at AMPA receptors on postsynaptic membranes. The drug was discovered at Eisai’s Tsukuba Research Laboratories. China’s NMPA reviewed Eisai’s NDA filing for Fycompa under Priority Review rules.
Source: China Biotoday
